CHARLOTTE – The Board of Directors of Durham-based Bioventus Inc. appointed Robert Claypoole as president and chief executive officer and a member of its board, effective January 10, 2024.
“We are excited to have Rob join Bioventus and build upon the significant improvements made this year to further elevate our execution and overall performance,” said William A. Hawkins, Bioventus’ executive chairman. “Throughout his career, Rob has demonstrated first-hand his ability at unlocking value opportunities across a global business. His track record is marked by consistently driving commercial and operational excellence, resulting in above-market sales growth and enhanced profitability. Moreover, Rob has a history of cultivating high-performing teams with a laser focus on execution.”
Claypoole, who most recently served as executive VP at Mölnlycke Health Care AB, succeeds Anthony Bihl who has served as interim CEO since April.
Claypoole led Mölnlycke’s $1.2 billion global Wound Care business. He also has had senior positions at Medtronic, Covidien and Johnson & Johnson, according to Bioventus.
